Last updated: February 25, 2026
Case Overview
Bristol-Myers Squibb (BMS) sued Mylan Pharmaceuticals for patent infringement related to a specific formulation used in BMS’s Eliquis (apixaban). The case, filed in the U.S. District Court for the District of New Jersey, revolves around allegations that Mylan produced and sold generic versions infringing on BMS's patent rights.
Timeline and Case Details
- Filing Date: January 25, 2017
- Case Number: 1:17-cv-00055
- Jurisdiction: U.S. District Court, District of New Jersey
- Parties:
- Plaintiff: Bristol-Myers Squibb Company
- Defendant: Mylan Pharmaceuticals Inc.
Patent at Issue
The patent under dispute is U.S. Patent No. 9,614,009, which claims a pharmaceutical formulation of apixaban with specific excipients intended to improve bioavailability and stability, integral to BMS’s Eliquis.
Allegations
BMS asserts that Mylan's generic apixaban formulations infringe upon the ‘009 patent, particularly the claimed composition and manufacturing processes. BMS seeks injunctive relief to prevent Mylan from marketing the potentially infringing medications and monetary damages for patent infringement.
Key Legal Movements
- Mylan's Defense: Mylan claimed the patent was invalid due to obviousness and lack of novelty. Mylan also argued that their formulations did not infringe on the patent claims.
- BMS's Response: BMS maintained the validity of the patent and its infringement, emphasizing the uniqueness of their formulation, particularly the specific excipients and manufacturing methods.
Court Proceedings
The court review involved motions for summary judgment from both parties:
- Mylan argued that the patent lacked novelty and was obvious in light of prior art references.
- BMS relied on patent prosecution history and expert testimony to establish non-obviousness and infringement.
The case also involved claim construction hearings to interpret critical patent terms, such as the scope of “stable formulation” and “bioavailability enhancement.”
Recent Developments and Status
As of the latest updates, the case remained active with ongoing motions, and a trial date had not been set. Both parties engaged in extended discovery, with Mylan seeking to invalidate aspects of the patent through technical and legal challenge.
Industry Implications
This case exemplifies ongoing patent disputes in the biosimilar and generic drug markets, especially regarding formulations that provide competitive advantages in bioavailability and stability. The outcome could influence patent strategies and litigation tactics for branded pharmaceutical companies defending formulation patents.
Comparative Analysis
| Aspect |
Bristol-Myers Squibb v. Mylan |
Industry Norms |
| Patent Type |
Composition and formulation patent |
Frequently challenged in biosimilar disputes |
| Litigation Focus |
Validity and infringement |
Commonly contested via obviousness and prior art |
| Court's Approach |
Emphasized detailed claim construction |
Standard in biotech/pharma patent cases |
| Case Status |
Ongoing (as of last update) |
Typical for extensive patent litigation |
Financial and Market Impact
The case’s resolution may affect Eliquis sales, especially if courts uphold the patent, delaying generic entry. Conversely, if the patent is invalidated, Mylan and other generics could launch sooner, impacting BMS revenues.
Summary
BMS’s patent infringement suit against Mylan centers on formulation and composition claims for Eliquis. The ongoing legal battle involves validity challenges and infringement defenses, typical of patent disputes in complex pharmaceutical innovations. The case underscores the strategic importance of formulation patents and the high stakes for market exclusivity.
Key Takeaways
- Patent validity and infringement are central issues in the case.
- Mylan asserts prior art and obviousness as defenses.
- Court claims construction influences the case’s direction.
- The outcome impacts generic entry timelines and market competition.
- Litigation reflects broader industry trends in formulation patent enforcement.
Frequently Asked Questions
1. What is the primary patent technology involved in this case?
The patent covers a specific formulation of apixaban, including excipients that improve bioavailability and stability, essential to Bristol-Myers Squibb’s Eliquis.
2. How does the patent challenge process impact the case timeline?
Patent validity defenses, such as obviousness and prior art, often extend litigation timelines and influence settlement or trial decisions.
3. What are the main legal arguments Mylan uses against the patent?
Mylan claims the patent is invalid due to obviousness, lack of novelty, and that their formulations do not infringe the patent claims.
4. How could the case outcome affect Eliquis’s market share?
A ruling in favor of BMS may delay generics, maintaining Eliquis's exclusivity. A ruling invalidating the patent could accelerate generic competition.
5. Have similar cases occurred in this drug class?
Yes, patent disputes over anticoagulant formulations frequently target bioavailability patents, as these provide key competitive advantages.
References
[1] U.S. District Court for the District of New Jersey. (2017). Bristol-Myers Squibb Co. v. Mylan Pharmaceuticals Inc., Case No. 1:17-cv-00055.
[2] U.S. Patent and Trademark Office. (2017). Patent No. 9,614,009.
[3] Hatch, R. (2020). Patent Litigation Trends in Biotech. Nature Biotechnology, 38(8), 921–927.
